PA8815001A1 - Piridinil amidas para el tratamiento de trastornos del snc y metabolicos - Google Patents

Piridinil amidas para el tratamiento de trastornos del snc y metabolicos

Info

Publication number
PA8815001A1
PA8815001A1 PA20098815001A PA8815001A PA8815001A1 PA 8815001 A1 PA8815001 A1 PA 8815001A1 PA 20098815001 A PA20098815001 A PA 20098815001A PA 8815001 A PA8815001 A PA 8815001A PA 8815001 A1 PA8815001 A1 PA 8815001A1
Authority
PA
Panama
Prior art keywords
treatment
piridinil
amidas
cns
metabolic disorders
Prior art date
Application number
PA20098815001A
Other languages
English (en)
Inventor
Martha Collantes Elizabeth
Bradley Schwarz Jacob
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8815001A1 publication Critical patent/PA8815001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0004—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements comprising amorphous/crystalline phase transition cells
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/0023—Address circuits or decoders
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/003—Cell access
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L27/00—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate
    • H01L27/02—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers
    • H01L27/04—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body
    • H01L27/10—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration
    • H01L27/102—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration including bipolar components
    • H01L27/1021—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration including bipolar components including diodes only
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/72—Array wherein the access device being a diode
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/74—Array wherein each memory cell has more than one access device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/78—Array wherein the memory cells of a group share an access device, all the memory cells of the group having a common electrode and the access device being not part of a word line or a bit line driver
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/79—Array wherein the access device being a transistor
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/02—Disposition of storage elements, e.g. in the form of a matrix array
    • G11C5/025—Geometric lay-out considerations of storage- and peripheral-blocks in a semiconductor storage device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/06—Arrangements for interconnecting storage elements electrically, e.g. by wiring
    • G11C5/063—Voltage and signal distribution in integrated semi-conductor memory access lines, e.g. word-line, bit-line, cross-over resistance, propagation delay

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Power Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Computer Hardware Design (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE PIRIDINILO DE FÓRMULA EN LA QUE Y, Z, L, R1 A R11, N, M, P, C, T SON COMO SE HAN DEFINIDO EN ESTE DOCUMENTO, QUE SON LIGANDOS DEL RECEPTOR 5-HT, PARTICULARMENTE DEL SUBTIPO 5-HT6, Y COMO TALES SON ÚTILES PARA TRATAR ENFERMEDADES EN LAS QUE SE DESEA LA MODULACIÓN DE LA ACTIVIDAD DE 5-HT. LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE PIRIDINILO INCLUYENDO SUS SALES FARMACÉUTICAMENTE ACEPTABLES. LA INVENCIÓN TAMBIÉN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACIÓN DE, A INTERMEDIOS USADOS EN LA PREPARACIÓN DE, A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN, Y A LOS USOS DE, DICHOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL TALES COMO ESQUIZOFRENIA.
PA20098815001A 2008-02-05 2009-02-04 Piridinil amidas para el tratamiento de trastornos del snc y metabolicos PA8815001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2619508P 2008-02-05 2008-02-05

Publications (1)

Publication Number Publication Date
PA8815001A1 true PA8815001A1 (es) 2009-09-17

Family

ID=40680365

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098815001A PA8815001A1 (es) 2008-02-05 2009-02-04 Piridinil amidas para el tratamiento de trastornos del snc y metabolicos

Country Status (11)

Country Link
US (1) US20090197859A1 (es)
EP (1) EP2265600A1 (es)
JP (1) JP2011511056A (es)
AR (1) AR070343A1 (es)
CA (1) CA2714232A1 (es)
CL (1) CL2009000245A1 (es)
PA (1) PA8815001A1 (es)
PE (1) PE20091379A1 (es)
TW (1) TW200938532A (es)
UY (1) UY31632A1 (es)
WO (1) WO2009098576A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8710076B2 (en) * 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
TW201041869A (en) 2009-05-14 2010-12-01 Japan Tobacco Inc Azetidine compound and pharmaceutical use thereof
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2576539B1 (de) 2010-05-27 2017-12-13 Bayer CropScience AG Pyridinylcarbonsäure derivate als fungizide
US9012636B2 (en) 2010-10-29 2015-04-21 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
EP2909193B1 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104995170A (zh) * 2013-02-14 2015-10-21 盖尔德马研究及发展公司 合成4-哌啶-4-基-苯-1,3-二醇及其盐以及新型化合物4-(2,4-二羟基-苯基)-4-羟基-哌啶-1-甲酸叔丁酯的方法
US20160009697A1 (en) * 2013-02-21 2016-01-14 Selvita S.A. Pyridine derivatives as 5-ht6 receptor antagonists
US9725434B2 (en) * 2013-04-23 2017-08-08 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
CN109721530A (zh) * 2017-10-31 2019-05-07 成都博腾药业有限公司 一种制备6-氟-2-吡啶磺酰氯的方法
CA3147471A1 (en) 2019-07-30 2021-02-04 Karl-Franzens-Universitat Graz Inhibitors of human atgl

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase

Also Published As

Publication number Publication date
UY31632A1 (es) 2009-09-30
TW200938532A (en) 2009-09-16
EP2265600A1 (en) 2010-12-29
AR070343A1 (es) 2010-03-31
WO2009098576A1 (en) 2009-08-13
JP2011511056A (ja) 2011-04-07
PE20091379A1 (es) 2009-09-18
US20090197859A1 (en) 2009-08-06
CA2714232A1 (en) 2009-08-13
CL2009000245A1 (es) 2009-06-05

Similar Documents

Publication Publication Date Title
PA8815001A1 (es) Piridinil amidas para el tratamiento de trastornos del snc y metabolicos
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
CR20120562A (es) Compuestos heterocíclicos y sus usos
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
UY31623A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
CO6400220A2 (es) Derivados de sulfonamida
ECSP14013215A (es) Compuestos novedosos
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
DOP2015000147A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.